Patent vs Trade Secret in Germany: Which IP Protection Should Life‑sciences Companies Choose?
Every pharma, medtech and digital‑health company commercialising in Germany faces a concrete fork in the road: file a patent and gain time‑limited exclusivity in exchange for full public disclosure…
Read the full articleYou might also wanna read
‘How did they get there first?’ Biotechs forced to learn new patent tricks to protect pipelines
For a biotech, your intellectual property is your most prized asset. But a new era of increased global competition means that strong patents
Patalyze: KI für Patententscheidungen
Ob ein neues Produkt bestehende Patente verletzt, zu prüfen dauert bislang oft Wochen und kostet tausende Euro. Das Münchner Legaltech Patal
Harmonising access and reinventing the procurement of innovative medicines in Europe
Europe pays for innovative medicines through 27 uncoordinated national negotiations, generating access delays, cross-country pricing externa
AI and Patent Strategy in Life Sciences – Part 4: Using Recurring FTO Monitoring to Mitigate Patent Risk
Part 4: How recurring freedom-to-operate monitoring may help life-science companies and investors find patent risk before it becomes litigat
jdsupra.com·3d ago
Parallel importation of pharmaceuticals in the US and Europe
Pharmaceuticals Discussion Intellectual Property Partner, Nick Phillips discusses parallel importation of pharmaceuticals in the US and Euro
STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
German lawmakers passed a bill that would more than double the discount on branded medicines drugmakers must provide the government
Comments
Sign in to join the conversation.
No comments yet. Be the first.